ERTS Wealth Advisors LLC increased its holdings in shares of Sanofi SA (NYSE:SNY) by 3.0% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 8,844 shares of the company’s stock after purchasing an additional 259 shares during the quarter. ERTS Wealth Advisors LLC’s holdings in Sanofi were worth $383,000 as of its most recent filing with the SEC.

Other large investors have also recently added to or reduced their stakes in the company. NumerixS Investment Technologies Inc increased its position in Sanofi by 218.8% during the 1st quarter. NumerixS Investment Technologies Inc now owns 17,800 shares of the company’s stock worth $788,000 after buying an additional 12,216 shares during the period. Cetera Advisors LLC purchased a new position in Sanofi in the second quarter worth $293,000. Sontag Advisory LLC purchased a new position in Sanofi in the second quarter worth $284,000. Coastal Investment Advisors Inc. boosted its position in Sanofi by 96.1% in the second quarter. Coastal Investment Advisors Inc. now owns 3,251 shares of the company’s stock worth $139,000 after purchasing an additional 1,593 shares during the last quarter. Finally, Dearborn Partners LLC purchased a new position in Sanofi in the second quarter worth $251,000. 7.04% of the stock is owned by hedge funds and other institutional investors.

Several research firms have weighed in on SNY. Sanford C. Bernstein began coverage on Sanofi in a research report on Tuesday, September 3rd. They issued an “outperform” rating and a $52.00 price objective on the stock. TheStreet raised Sanofi from a “c+” rating to a “b-” rating in a research report on Friday, June 21st. UBS Group raised Sanofi from a “neutral” rating to a “buy” rating in a research report on Wednesday, August 14th. Zacks Investment Research raised Sanofi from a “hold” rating to a “buy” rating and set a $47.00 price objective on the stock in a research report on Thursday, August 29th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a research report on Tuesday, August 6th. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Sanofi currently has a consensus rating of “Buy” and a consensus target price of $49.67.

In other Sanofi news, major shareholder Sanofi bought 93,750 shares of the firm’s stock in a transaction on Monday, July 22nd. The shares were acquired at an average cost of $16.00 per share, for a total transaction of $1,500,000.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.00% of the stock is owned by corporate insiders.

Shares of NYSE SNY traded up $0.09 during trading on Friday, reaching $43.89. 169,972 shares of the stock traded hands, compared to its average volume of 1,238,636. Sanofi SA has a 52-week low of $40.00 and a 52-week high of $45.62. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85. The company has a 50-day moving average of $42.58 and a 200-day moving average of $42.71. The stock has a market capitalization of $109.48 billion, a P/E ratio of 14.01, a price-to-earnings-growth ratio of 2.41 and a beta of 0.67.

Sanofi (NYSE:SNY) last issued its quarterly earnings data on Monday, July 29th. The company reported $0.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.07. The business had revenue of $8.63 billion for the quarter, compared to analysts’ expectations of $8.42 billion. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. The firm’s quarterly revenue was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.25 EPS. Analysts expect that Sanofi SA will post 3.1 earnings per share for the current fiscal year.

About Sanofi

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Recommended Story: What does cost of debt say about a company’s financial health?

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.